{"id":32097,"date":"2025-07-30T08:38:15","date_gmt":"2025-07-30T08:38:15","guid":{"rendered":"https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/"},"modified":"2025-07-30T08:38:15","modified_gmt":"2025-07-30T08:38:15","slug":"a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/","title":{"rendered":"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19"},"content":{"rendered":"<p>MARIA JESUS LOPEZ FERNANDEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; HIPRA SCIENTIFIC SLU<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MARIA JESUS LOPEZ FERNANDEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; HIPRA SCIENTIFIC SLU<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2272],"tags":[],"class_list":["post-32097","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-a-23-ensayos-clinicos"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19 - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19 - Ibima\" \/>\n<meta property=\"og:description\" content=\"MARIA JESUS LOPEZ FERNANDEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; HIPRA SCIENTIFIC SLU\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:38:15+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19\",\"datePublished\":\"2025-07-30T08:38:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\\\/\"},\"wordCount\":52,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - A-23\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\\\/\",\"name\":\"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19 - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:38:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19 - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/","og_locale":"es_ES","og_type":"article","og_title":"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19 - Ibima","og_description":"MARIA JESUS LOPEZ FERNANDEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; II &#8211; HIPRA SCIENTIFIC SLU","og_url":"https:\/\/ibima.eu\/es\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:38:15+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19","datePublished":"2025-07-30T08:38:15+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/"},"wordCount":52,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - A-23"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/","url":"https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/","name":"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19 - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:38:15+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/a-phase-ii-randomized-double-blind-multi-centre-trial-to-evaluate-the-safety-and-immunogenicity-of-bimervax-when-coadministered-with-seasonal-surface-antigen-inactivated-adjuvanted-influenz\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX\u00ae when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=32097"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32097\/revisions"}],"predecessor-version":[{"id":55072,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32097\/revisions\/55072"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=32097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=32097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=32097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}